34 min
Learnings from NCI-MATCH The Cancer Trials Ireland Podcast
-
- Science
Although the NCI-MATCH precision medicine cancer trial has now wrapped up, we are still learning a lot from this enormous initiative.
Today we hear from co-chair of NCI-MATCH about the results, what it has taught us about genomics and what it means for the future of cancer treatment.
Our guest is Peter J. O’Dwyer, MD, a GI medical oncologist, Group Co-Chair of the ECOG-ACRIN Cancer Research Group, and professor of medicine at the University of Pennsylvania. Within ECOG-ACRIN, he co-chairs the landmark NCI-MATCH precision medicine cancer trial, and is the CEO and Chair of PrECOG.
THINGS WE SPOKE ABOUT
● An introduction to Peter O’Dwyer
● How clinical trials have changed over time
● The evolving area of genomic tests
● Why Next Generation Sequencing should be considered
● A Summary of the NCI-MATCH Trial
● How to improve activity
● Corporate approved settings could be optimal setting for studies
● Advice for clinicians on Next Generation Sequencing
● Improvements in treatment for pancreatic cancer
GUEST DETAILS
Peter J. O’Dwyer, MD, is a GI medical oncologist, Group Co-Chair of the ECOG-ACRIN Cancer Research Group, and professor of medicine at the University of Pennsylvania. Within ECOG-ACRIN, he co-chairs the landmark NCI-MATCH precision medicine cancer trial. He is also the CEO of PrECOG, which develops and leads cancer clinical trials in partnership with industry.
Dr. O’Dwyer received his medical degree at the University of Dublin, Trinity College. Dr. O’Dwyer has published over 350 scientific papers, and participates in numerous national and international organisations.
https://ecog-acrin.org/about-us/governance/peter-odwyer/
MORE INFORMATION
Cancer Trials Ireland is a registered charity and the leading cancer research trials organisation in Ireland. It aims to provide every patient with cancer access to high-quality and potentially life-altering cancer trials and to make Ireland a highly attractive location to open cancer trials.
Since 2000, 623 cancer trials have opened in Ireland, with more than 33,500 patients taking part. In 2022, a survey of public attitudes revealed three in five people in Ireland would take part in a clinical trial. Almost all cancer clinical trials available in Ireland are listed on the Cancer Trials Ireland website: www.cancertrials.ie/open-trials.
Cancer Trials Ireland is partly funded by the Health Research Board and the Irish Cancer Society. It also receives income from pharmaceutical companies and international research groups, as well as through philanthropic giving and donations from members of the public.
Since 2017, Cancer Trials Ireland has rolled out an annual campaign (Just Ask) to promote public awareness and understanding of clinical trials and associated issues. Just Ask 2023 is support through unrestricted grants from AbbVie, Bayer, MSD, Novartis, & Pfizer.
KEYWORDS
#clinicaltrials, #cancerireland #tumors #genomic #immunotherapy #pancreatic cancer
Hosted on Acast. See acast.com/privacy for more information.
Although the NCI-MATCH precision medicine cancer trial has now wrapped up, we are still learning a lot from this enormous initiative.
Today we hear from co-chair of NCI-MATCH about the results, what it has taught us about genomics and what it means for the future of cancer treatment.
Our guest is Peter J. O’Dwyer, MD, a GI medical oncologist, Group Co-Chair of the ECOG-ACRIN Cancer Research Group, and professor of medicine at the University of Pennsylvania. Within ECOG-ACRIN, he co-chairs the landmark NCI-MATCH precision medicine cancer trial, and is the CEO and Chair of PrECOG.
THINGS WE SPOKE ABOUT
● An introduction to Peter O’Dwyer
● How clinical trials have changed over time
● The evolving area of genomic tests
● Why Next Generation Sequencing should be considered
● A Summary of the NCI-MATCH Trial
● How to improve activity
● Corporate approved settings could be optimal setting for studies
● Advice for clinicians on Next Generation Sequencing
● Improvements in treatment for pancreatic cancer
GUEST DETAILS
Peter J. O’Dwyer, MD, is a GI medical oncologist, Group Co-Chair of the ECOG-ACRIN Cancer Research Group, and professor of medicine at the University of Pennsylvania. Within ECOG-ACRIN, he co-chairs the landmark NCI-MATCH precision medicine cancer trial. He is also the CEO of PrECOG, which develops and leads cancer clinical trials in partnership with industry.
Dr. O’Dwyer received his medical degree at the University of Dublin, Trinity College. Dr. O’Dwyer has published over 350 scientific papers, and participates in numerous national and international organisations.
https://ecog-acrin.org/about-us/governance/peter-odwyer/
MORE INFORMATION
Cancer Trials Ireland is a registered charity and the leading cancer research trials organisation in Ireland. It aims to provide every patient with cancer access to high-quality and potentially life-altering cancer trials and to make Ireland a highly attractive location to open cancer trials.
Since 2000, 623 cancer trials have opened in Ireland, with more than 33,500 patients taking part. In 2022, a survey of public attitudes revealed three in five people in Ireland would take part in a clinical trial. Almost all cancer clinical trials available in Ireland are listed on the Cancer Trials Ireland website: www.cancertrials.ie/open-trials.
Cancer Trials Ireland is partly funded by the Health Research Board and the Irish Cancer Society. It also receives income from pharmaceutical companies and international research groups, as well as through philanthropic giving and donations from members of the public.
Since 2017, Cancer Trials Ireland has rolled out an annual campaign (Just Ask) to promote public awareness and understanding of clinical trials and associated issues. Just Ask 2023 is support through unrestricted grants from AbbVie, Bayer, MSD, Novartis, & Pfizer.
KEYWORDS
#clinicaltrials, #cancerireland #tumors #genomic #immunotherapy #pancreatic cancer
Hosted on Acast. See acast.com/privacy for more information.
34 min